Parkinson’s Disease, Multiple Sclerosis and Alzheimer’s Disease
Actos, traditionally used for diabetes has been shown to decrease the inflammation associated with neurological diseases with few side effects. It also doesn’t lower one’s glucose if one is not a diabetic. The decrease in inflammation is also not associated with the typical side effects associated with other anti-inflammatory like steroids.
Minocyclin, an antibiotic has been shown in recent studies to reduce inflammation in the brain and nervous system. Specifically has been shown to inhibit Astroglial cells, which are the immune cells found in the brain.
In my practice, I have seen excellent results with the use of these medications, especially when combined with various natural therapies that reduce inflammation and improve brain function. As suppose to other medications that are now available for these diseases, Actos and Minocyclin address the underline cause of these disorders: they reduce the primary inflammatory process in the brain. Once the inflammatory process is reduce through the use of these medications and detoxification of chemicals and heavy metals such as lead and mercury, I focus on improving brain function with various natural compounds, many of which are found in the brain. This is point where science and art meet because one has to not only know the science but one has to intuitively feel how these various natural compounds work in fellowship with our own biochemistry and cell function. Some of these natural compounds are novel and promising. They include a new compound Phosphatidylserine, attached to DHA, which is naturally found in the brain, Prevagen which has been shown to improve brain function, high potency Curcumin, IV and IM Glutathione, Lipostable and others.
Our patients see profound changes both in motor function and control and also in cognitive and overall brain function. Our approach to neurodegenerative diseases is a perfect example of how traditional medicine and holistic medicine must merge in order to offer patients the most effective treatments.
Publisher's abstract: New England Journal of Medicine.
Subjects from the "Framingham Study" were examined over an eight-year period. Baseline homocysteine levels measured eight years earlier were examined in relation to those individuals who developed dementia on follow-up. The study concluded that an increased homocysteine level is a strong, independent risk factor for the development of dementia and Alzheimer's disease. Occurrence of Alzheimer's nearly doubled in subjects with the highest level of homocysteine.
Healthy homocysteine levels can be maintained with a combination of Folate. B12 and B6. The body-ready (conenzymated) form of these vitamins may help overcome obstacles to metabolizing homocysteine.
COGNITIVE DISTURBANCES CORRESPOND WITH HIGH HOMOCYSTEINE 2
Publisher's abstract: Journal of Geriatric Psychiatry and Neurology.
When 101 patients complaining of cognitive disturbances were investigated using brain imaging, laboratory assessment, electroencephalography and Mini Mental State Evaluation, the results correlated high homocysteine in 33% of the patients with subjective memory complaints, 45% of patients with Alzheimer's disease, and 62% of the patients with vascular dementia.
HOMOCYSTEINE AND COGNITIVE DECLINE IN HEALTHY ELDERY 3
Publisher's abstract: Dement Geriatr Cogn Disord. Homocysteine appears to be an independent predictor of cognitive decline in healthy elderly and exerts a maximal effect on spatial copying skills.
BRAIN LESIONS AND SILENT STROKES RELATED TO HOMOCYSTEINE 4Publisher's abstract: Ann Neurol. Cerebral MRI scans revealed that as many as 28% of healthy people 60-90 years of age (1077 study participants) had white matter lesions and evidence of small strokes - two predictive indicators of dementia and stroke. Outcomes of the MRI scans were strongly associated with homocysteine levels, and the relationship was continuous with no obvious threshold below which homocysteine levels were not associated with risk of disease.
Healthy homocysteine levels can be maintained with a combination of Folate, B12 and B6. The body-ready (conenzymated) form of these vitamins may help overcome obstacles to metabolizing homocysteine.
Publisher's abstract: Arch Neurol. A three-year follow-up within the British OPTIMA project showed that patients with baseline homocysteine levels greater than 11.2 mmol/L showed a more rapid progression of atrophy of the medial temporal lobe (which includes hippocampus) over a three-year period.
IMPAIRED COGNITIVE ABILITIES MOST FREQUENT IN GROUP WITH HIGH HOMOCYSTEINE 6
Homocysteine Metabolism, 3rd International Conference 1-5 July 2001. Abstract 191.
The risk of impaired cognitive function (a decline of three or more points of the Mini Mental State Evaluation score) was almost four-fold among the 25% of subjects with the highest homocysteine levels, compared to subjects with 25% of the lowest values in a three year follow-up to a community based study of the elderly Dutch.
LOW FOLATE EQUALS HIGHER RISK FOR DEMENTIA OR COGNITIVE IMPARIMENT 7
Publisher's abstract: Dement Geriatr Cogn Disord.
The odds of developing vascular dementia, cognitive impairment or fatal stroke was 2.42 times higher for study participants with the lowest 25% of blood folate readings in a five-year follow-up study of 369 healthy subjects from the Canadian Study of Health and Aging.
HOMOCYSTEINE LEVELS AND CEREBROVASCULAR RISK FACTORS 8
Publisher's abstract: Arch Neurol.
Higher homocysteine levels are an independent risk factor for moderate to severe formation of cerebral white matter in individuals with Alzheimer's Disease, and of leukoaraiosis of the deep white matter in particular.
Healthy homocysteine levels can be maintained with a combination of Folate, B12 and B6. The body-ready (conenzymated) form of these vitamins may help overcome obstacles to metabolizing homocysteine.
Publisher's abstract: J Neurosci. Folate deficiency and homocysteine impair DNA repair in neurons, which sensitizes them to oxidative damage.
VASCULAR DAMAGE INDUCED BY HOMOCYSTEINE A RISK FACTOR FOR ALZHEIMERS DISEASE 10
Publisher's abstract: Nutr Rev. Homocysteine is considered an independent risk factor for vascular disease, and this finding is consistent with the emerging hypothesis that vascular disease is a contributing factor in the pathogenesis of Alzheimer's disease.
- Additional studies are underway to further demonstrate whether folate intake or lowering homocysteine levels consistently has a direct, causal role in risk reduction for memory decline, dementia or Alzheimer’s disease.
- This article is not intended to replace the advice or attention of your doctor or other health care professional. Do not stop taking medications or start taking any nutrition supplement without first speaking to a qualified health care professional who specialize in Alzheimer's care and disease.
Mary Joseph Foundation a non-profit organization for Alzheimer's disease.
No comments:
Post a Comment